Premium
Severe hyperglycaemia following pazopanib treatment: The role of drug‐drug‐gene interactions in a patient with metastatic renal cell carcinoma—A case report
Author(s) -
Kuruc Poje Darija,
Božida,
Šimičević Livija,
Žabić Igor
Publication year - 2020
Publication title -
journal of clinical pharmacy and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.622
H-Index - 73
eISSN - 1365-2710
pISSN - 0269-4727
DOI - 10.1111/jcpt.13160
Subject(s) - pazopanib , medicine , adverse effect , pharmacogenetics , renal cell carcinoma , pharmacology , tyrosine kinase inhibitor , drug , oncology , toxicity , cancer , sunitinib , genotype , biology , gene , biochemistry
What is known and objective Pazopanib is a tyrosine kinase inhibitor with hyperglycaemia as a known adverse event, but case reports of severe hyperglycaemia are exceptional. We report a case of severe hyperglycaemia following pazopanib administration in a patient with metastatic renal cell carcinoma. Case summary Severe hyperglycaemia developed in a patient one month following initiation of pazopanib therapy. As drug‐drug‐gene interactions may lead to hyperglycaemia, pharmacogenetic assessment was requested. The obtained findings indicated intermediate function of both OATP1B1 and P‐glycoprotein transporters, which may cause prolonged pazopanib bioavailability and increased toxicity. Pazopanib was discontinued and, following patient recovery, was reintroduced at a lower dose. What is new and Conclusion The pharmacogenetic profiling of the patient on polypharmacy enabled better management of pazopanib therapy.